002173.SZ
创新医疗
SZSE · Consumer Cyclical · Q 卫生 · CN
CNY 17.67
−3.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 754.6M | 781.3M | 816.0M | 805.6M | 709.7M |
| Cost of Revenue | 713.8M | 727.3M | 752.3M | 713.4M | 679.1M |
| Gross Profit | 40.8M | 54.0M | 63.7M | 92.2M | 30.6M |
| Operating Expenses | |||||
| R&D Expense | 4.3M | 3.1M | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 100.7M | 102.8M | 105.5M | 107.7M | 106.7M |
| Selling & Marketing Expense | 9.5M | 8.2M | 9.4M | 10.3M | 12.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 126.6M | 125.6M | 123.4M | 115.1M | 115.2M |
| Cost and Expenses | 840.4M | 852.9M | 875.7M | 828.5M | 794.3M |
| Operating Income (EBIT) | (43.1M) | (30.6M) | (60.3M) | (25.6M) | (78.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (41.4M) | (28.9M) | (100.6M) | (35.0M) | (75.3M) |
| Income Tax Expense | 7.3M | 7.4M | (6.6M) | (676.5K) | (1.7M) |
| Bottom Line | |||||
| Net Income | (46.1M) | (34.9M) | (94.0M) | (34.3M) | (73.4M) |
| Earnings from Cont. Ops | (48.7M) | (36.3M) | (94.0M) | (34.3M) | (73.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (46.1M) | (34.9M) | (94.0M) | (34.3M) | (73.4M) |
| Per Share | |||||
| Basic EPS | (CN¥0.11) | (CN¥0.08) | (CN¥0.21) | (CN¥0.08) | (CN¥0.16) |
| Diluted EPS | (CN¥0.11) | (CN¥0.08) | (CN¥0.21) | (CN¥0.08) | (CN¥0.16) |
| Revenue Per Share | CN¥1.80 | CN¥1.79 | CN¥1.82 | CN¥1.88 | CN¥1.55 |
| Shares | |||||
| Basic Shares Outstanding | 419.2M | 435.7M | 447.4M | 428.6M | 458.9M |
| Diluted Shares Outstanding | 419.2M | 435.7M | 447.4M | 428.6M | 458.9M |
| Profitability Metrics | |||||
| EBITDA | — | 63.3M | 38.6M | 77.1M | 29.6M |
| D&A | — | 93.9M | 98.9M | 102.7M | 108.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026